文献速递临床试验与 GCP基础与转化研究

单次高剂量维生素D3对中重度COVID-19患者住院时间的影响:一项随机临床试验

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

主要结局住院时间在两组间无显著差异,次要结局包括院内死亡、ICU入住和机械通气需求也均无显著差异。单次高剂量维生素D3未显著缩短住院时间,不支持将其用于中重度COVID-19的治疗。

要点

  • 维生素D3组与安慰剂组的院内死亡、ICU入住和机械通气需求均无显著差异。
  • 单次高剂量维生素D3可显著提高血清25-羟基维生素D水平,但未改善临床结局。

核心结论

  • 在中重度COVID-19住院患者中,与安慰剂相比,单次高剂量维生素D3未显著减少住院时间, findings 不支持将其用于中重度COVID-19的治疗。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验,在巴西圣保罗2个中心开展,纳入240例中重度COVID-19住院患者。

主要发现

  • 无不良事件报告,但有一次呕吐与干预相关。

临床怎么用

  • 本试验结果不支持对中重度COVID-19住院患者常规使用单次高剂量维生素D3以缩短住院时间或改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy of vitamin D3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear. OBJECTIVE: To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-blind, randomized, placebo-controlled trial conducted in 2 sites in Sao Paulo, Brazil. The study included 240 hospitalized patients with COVID-19 who were moderately to severely ill at the time of enrollment from June 2, 2020, to August 27, 2020. The final follow-up was on October 7, 2020. INTERVENTIONS: Patients were randomly assigned to receive a single oral dose of 200 000 IU of vitamin D3 (n = 120) or placebo (n = 120). MAIN OUTCOMES AND MEASURES: The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge. Prespecified secondary outcomes included mortality during hospitalization; the number of patients admitted to the intensive care unit; the number of patients who required mechanical ventilation and the duration of mechanical ventilation; and serum levels of 25-hydroxyvitamin D, total calcium, creatinine, and C-reactive protein. RESULTS: Of 240 randomized patients, 237 were included in the primary analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean [SD] baseline 25-hydroxyvitamin D level, 20.9 [9.2] ng/mL). Median (interquartile range) length of stay was not significantly different between the vitamin D3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank P = .59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; P = .62). The difference between the vitamin D3 group and the placebo group was not significant for in-hospital mortality (7.6% vs 5.1%; difference, 2.5% [95% CI, -4.1% to 9.2%]; P = .43), admission to the intensive care unit (16.0% vs 21.2%; difference, -5.2% [95% CI, -15.1% to 4.7%]; P = .30), or need for mechanical ventilation (7.6% vs 14.4%; difference, -6.8% [95% CI, -15.1% to 1.2%]; P = .09). Mean serum levels of 25-hydroxyvitamin D significantly increased after a single dose of vitamin D3 vs placebo (44.4 ng/mL vs 19.8 ng/mL; difference, 24.1 ng/mL [95% CI, 19.5-28.7]; P < .001). There were no adverse events, but an episode of vomiting was associated with the intervention. CONCLUSIONS AND RELEVANCE: Among hospitalized patients with COVID-19, a single high dose of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04449718.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33595634. doi:10.1001/jama.2020.26848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。